Adverse Pregnancy Outcomes in Adult Patients With Idiopathic Inflammatory Myopathy: A Systematic Review and Meta-Analysis.

Arthritis Care Res (Hoboken)Apr 21, 2026 (epub)
Clinical ResearchObstetrics & GynecologyRheumatology

Yang Yang, Danli Meng, Rongxiu Huo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the association between idiopathic inflammatory myopathy (IIM) and adverse pregnancy outcomes in adult patients. The analysis included five population-based cohorts, revealing that patients with IIM had significantly higher risks of hypertensive disorders of pregnancy (OR 2.73) and cesarean section (OR 2.03), as well as increased rates of preterm birth (OR 3.71) and small for gestational age infants (OR 1.90).

Key findings

  • Patients with IIM had a 2.73-fold increased risk of hypertensive disorders of pregnancy.
  • The risk of cesarean section was 2.03 times higher in patients with IIM.
  • Infants born to patients with IIM had a 3.71-fold increased risk of being born preterm.
  • The odds of infants being small for gestational age were 1.90 times higher in IIM patients.

Why it matters

Understanding the increased risks associated with IIM during pregnancy is crucial for clinicians to manage and monitor affected patients effectively, ensuring better maternal and fetal outcomes.

Source

PubMed · PMID 41869994

Published in Arthritis Care Res (Hoboken). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.